John Granton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11479920/publications.pdf

Version: 2024-02-01

117625 91884 8,103 69 34 69 h-index citations g-index papers 71 71 71 8217 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	High-Frequency Oscillatory Ventilation in Adults. Chest, 2004, 126, 518-527.	0.8	1,201
2	Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials. PLoS ONE, 2012, 7, e47559.	2.5	906
3	Bosentan Therapy in Patients With Eisenmenger Syndrome. Circulation, 2006, 114, 48-54.	1.6	773
4	Updated Treatment Algorithm of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2013, 62, D60-D72.	2.8	596
5	High-Frequency Oscillatory Ventilation for Acute Respiratory Distress Syndrome in Adults. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 801-808.	5.6	588
6	Daily Sedation Interruption in Mechanically Ventilated Critically III Patients Cared for With a Sedation Protocol. JAMA - Journal of the American Medical Association, 2012, 308, 1985.	7.4	402
7	Bone Morphogenetic Protein Receptor-2 Signaling Promotes Pulmonary Arterial Endothelial Cell Survival. Circulation Research, 2006, 98, 209-217.	4.5	287
8	Prevalence, Risk Factors, and Outcomes of Delirium in Mechanically Ventilated Adults*. Critical Care Medicine, 2015, 43, 557-566.	0.9	268
9	Intensive Care Unit Management of Patients with Severe Pulmonary Hypertension and Right Heart Failure. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1114-1124.	5.6	259
10	Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension study. International Journal of Cardiology, 2008, 127, 27-32.	1.7	215
11	Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis. EClinicalMedicine, 2020, 19, 100249.	7.1	150
12	Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study. BMJ Open Respiratory Research, 2017, 4, e000183.	3.0	148
13	Clinical trial design and new therapies for pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1801908.	6.7	142
14	Prophylaxis Against Deep Vein Thrombosis in Critically Ill Patients With Severe Renal Insufficiency With the Low-Molecular-Weight Heparin Dalteparin <subtitle>An Assessment of Safety and Pharmacodynamics: The DIRECT Study</subtitle> . Archives of Internal Medicine, 2008, 168, 1805.	3.8	133
15	Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension. Circulation Research, 2015, 117, 645-654.	4.5	120
16	The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. Journal of Critical Care, 2010, 25, 287-293.	2,2	117
17	Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 337-347.	5.6	115
18	Metabolomic Heterogeneity of Pulmonary Arterial Hypertension. PLoS ONE, 2014, 9, e88727.	2.5	111

#	Article	IF	CITATIONS
19	A randomized trial of daily awakening in critically ill patients managed with a sedation protocol: A pilot trial*. Critical Care Medicine, 2008, 36, 2092-2099.	0.9	107
20	Prevalence, risk factors, and outcomes associated with physical restraint use in mechanically ventilated adults. Journal of Critical Care, 2016, 31, 31-35.	2.2	85
21	In-house, overnight physician staffing: A cross-sectional survey of Canadian adult and pediatric intensive care units*. Critical Care Medicine, 2006, 34, 1674-1678.	0.9	83
22	Patient safety, resident well-being and continuity of care with different resident duty schedules in the intensive care unit: a randomized trial. Cmaj, 2015, 187, 321-329.	2.0	80
23	Effects of Recipient Age and Diagnosis on Health-related Quality-of-Life Benefit of Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 965-973.	5.6	76
24	Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. Journal of Critical Care, 2005, 20, 364-372.	2.2	70
25	Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin prophylaxis: prevalence, incidence and risk factors. Critical Care, 2008, 12, R32.	5.8	68
26	Diagnostic Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension: A Clinical Practice Guideline. Canadian Respiratory Journal, 2010, 17, 301-334.	1.6	68
27	Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: A subgroup analysis. International Journal of Cardiology, 2010, 144, 373-378.	1.7	64
28	Effects of Mesenchymal Stem Cell Treatment on Systemic Cytokine Levels in a Phase 1 Dose Escalation Safety Trial of Septic Shock Patients*. Critical Care Medicine, 2019, 47, 918-925.	0.9	58
29	Critical care capacity in Canada: results of a national cross-sectional study. Critical Care, 2015, 19, 133.	5.8	55
30	Risk quantification of early outcome after lung transplantation: donor, recipient, operative, and post-transplant parameters. Journal of Heart and Lung Transplantation, 2004, 23, 96-104.	0.6	51
31	Long-term outcomes after pulmonary embolism. Blood Coagulation and Fibrinolysis, 2014, 25, 407-415.	1.0	49
32	Cardiac ischemia in patients with septic shock randomized to vasopressin or norepinephrine. Critical Care, 2013, 17, R117.	5.8	43
33	A Biochemical Approach to Understand the Pathogenesis of Advanced Pulmonary Arterial Hypertension: Metabolomic Profiles of Arginine, Sphingosine-1-Phosphate, and Heme of Human Lung. PLoS ONE, 2015, 10, e0134958.	2.5	41
34	Risk factors for mortality in patients admitted to intensive care units with pneumonia. Respiratory Research, 2016, 17, 80.	3.6	39
35	Pulmonary endarterectomy in severe chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2015, 34, 369-375.	0.6	37
36	Recall of ICU Stay in Patients Managed With a Sedation Protocol or a Sedation Protocol With Daily Interruption. Critical Care Medicine, 2015, 43, 2180-2190.	0.9	36

#	Article	IF	CITATIONS
37	De novo synthesize of bile acids in pulmonary arterial hypertension lung. Metabolomics, 2014, 10, 1169-1175.	3.0	35
38	Agreement in electrocardiogram interpretation in patients with septic shock*. Critical Care Medicine, 2011, 39, 2080-2086.	0.9	34
39	Pulmonary arterial hypertension in pregnancyâ€"a systematic review of outcomes in the modern era. Pulmonary Circulation, 2021, 11, 1-9.	1.7	34
40	Update of early respiratory failure in the lung transplant recipient. Current Opinion in Critical Care, 2006, 12, 19-24.	3.2	32
41	Recall of intensive care unit stay in patients managed with a sedation protocol or a sedation protocol with daily sedative interruption: A pilot study. Journal of Critical Care, 2011, 26, 127-132.	2.2	32
42	Management of Severe Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 700-713.	2.1	27
43	Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Canadian Respiratory Journal, 2008, 15, 77-83.	1.6	26
44	Comparative Safety and Tolerability of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension. Drug Safety, 2015, 38, 419-435.	3.2	25
45	Symptoms Are More Useful Than Echocardiography in Patient Selection forÂPulmonary Endarterectomy. Annals of Thoracic Surgery, 2017, 104, 1179-1185.	1.3	21
46	Use of a screen log to audit patient recruitment into multiple randomized trials in the intensive care unit. Critical Care Medicine, 2000, 28, 867-871.	0.9	20
47	Feasibility of Internet-Based Health-Related Quality of Life Data Collection in a Large Patient Cohort. Journal of Medical Internet Research, 2010, 12, e35.	4.3	18
48	ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery. Journal of Heart and Lung Transplantation, 2022, 41, 1135-1194.	0.6	17
49	Role of extracorporeal life support after pulmonary endarterectomy: a single-centre experience. Interactive Cardiovascular and Thoracic Surgery, 2016, 23, 74-78.	1.1	16
50	Adult hemophagocytic lymphohistiocytosis with severe pulmonary hypertension and a novel perforin gene mutation. International Journal of Hematology, 2012, 95, 445-450.	1.6	15
51	Riociguat for the treatment of pulmonary hypertension. Expert Review of Respiratory Medicine, 2015, 9, 679-695.	2.5	15
52	PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT): A Pilot Study Blood, 2004, 104, 1784-1784.	1.4	14
53	Pulmonary hypertension after pulmonary emboli: an underrecognized condition. Cmaj, 2006, 174, 1706-1706.	2.0	11
54	Pulmonary Arterial Hypertension: A Palliative Medicine Review of the Disease, Its Therapies, and Drug Interactions. Journal of Pain and Symptom Management, 2020, 59, 932-943.	1.2	10

#	Article	IF	CITATIONS
55	Central venoarterial extracorporeal membrane oxygenation as a bridge to recovery after pulmonary endarterectomy in patients with decompensated right heart failure. Journal of Heart and Lung Transplantation, 2022, 41, 773-779.	0.6	9
56	Importance of computed tomography in defining segmental disease in chronic thromboembolic pulmonary hypertension. ERJ Open Research, 2020, 6, 00461-2020.	2.6	8
57	Outcome after pulmonary endarterectomy for segmental chronic thromboembolic pulmonary hypertension. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 696-707.e4.	0.8	7
58	Pulmonary endarterectomy in severe chronic thromboembolic pulmonary hypertension: the Toronto experience. Annals of Cardiothoracic Surgery, 2022, 11, 133-142.	1.7	6
59	Canadian Cardiovascular Society and Canadian Thoracic Society Position Statement on Pulmonary Arterial Hypertension. Canadian Respiratory Journal, 2005, 12, 303-315.	1.6	5
60	Lung Transplantation for Pulmonary Hypertension and Strategies to Bridge to Transplant. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 701-710.	2.1	5
61	Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension: New Horizons in the Interventional Management of Pulmonary Embolism. Techniques in Vascular and Interventional Radiology, 2017, 20, 206-215.	1.0	5
62	Temporal shifts in fluid in pulmonary hypertension with and without sleep apnea. Journal of Sleep Research, 2019, 28, e12863.	3.2	4
63	Under Pressure. New England Journal of Medicine, 2010, 362, 449-454.	27.0	3
64	Cellular immunotherapy for septic shock (CISS): a phase I trial. Cytotherapy, 2017, 19, e3-e4.	0.7	2
65	In-House, Overnight Physician Staffing: A Cross-Sectional Survey of Canadian Adult ICUs. Critical Care Medicine, 2020, 48, e1203-e1210.	0.9	2
66	Outcomes in pulmonary hypertension: Beyond 40 metres. Canadian Journal of Cardiology, 2010, 26, 12B-16B.	1.7	1
67	Serial assessment of systemic levels of proinflammatory cytokines in septic shock patients treated with allogeneic mesenchymal stem cells. Cytotherapy, 2017, 19, e5.	0.7	1
68	A Case of Pulmonary Arterial Hypertension Associated with Adult Hemophagocytic Lymphohistiocytosis. Pulmonary Circulation, 2016, 6, 614-615.	1.7	1
69	Pharmacology of theÂPulmonary Circulation. , 2019, , 165-179.		0